NextCure, Inc. (NXTC)
$6.58+4.78%Close
BUYRECOVERY · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $24M
- Beta
- 1.35
- P/E (TTM)
- -0.62
- Short % float
- 9.44%
- Days to cover
- 1.9
- SI change
- +102.7%
- 1W
- +0.30%
- 1M
- +3.30%
- vs SPY 1W
- +0.44%
- vs SPY 1M
- +0.79%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 12
- GROWTH
- 43
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-105.3%
REV YoY-
ROE-175.5%
EPS YoY-
ROA-189.0%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.62
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.88
P/FCF-
EV/EBITDA-0.46
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E35.29
ALTMAN Z-
CURR RATIO3.47
ND/EBITDA-
BETA1.35
Company news
FAQ
- What is LOPJLB’s current signal on NXTC?
- LOPJLB’s latest quantitative signal on NextCure, Inc. (NXTC) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is NXTC in?
- NextCure, Inc. (NXTC) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does NextCure, Inc. (NXTC) do?
- NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metast…